Top 10 Companies in the (S)-(4-Nitrophenyl) ethylamine (CAS 4187-53-5) Market (2026): Market Leaders Powering Global Chemical Innovation

MARKET INSIGHTS

Global (S)-(4-Nitrophenyl) ethylamine (CAS 4187-53-5) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(S)-(4-Nitrophenyl) ethylamine (CAS 4187-53-5) is a chiral amine compound characterized by a nitrophenyl aromatic ring with a single stereocenter in the (S)-configuration. It serves as a critical building block in asymmetric synthesis and pharmaceutical intermediate chemistry, particularly in the production of optically active APIs, agrochemicals, and fine chemicals. Its high enantiomeric purity makes it especially valuable in drug development pipelines where stereoselectivity is essential.

The market is witnessing steady growth driven by rising demand for enantiopure intermediates in pharmaceutical manufacturing and expanding applications in chiral catalyst development. Furthermore, increased investment in asymmetric synthesis technologies and the growing focus on precision medicine are reinforcing demand. Key suppliers operating in this space include TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar, among other specialty fine chemical manufacturers serving global research and industrial customers.

(S)-(4-Nitrophenyl) ethylamine (CAS 4187-53-5) Market – View in Detailed Research Report

MARKET DRIVERS

Rising demand in pharmaceutical synthesis and chiral chemistry is a key driver, as the compound’s well‑defined stereochemistry is essential for the development of single‑enantiomer drugs. Expanding use in agrochemical and fine chemical research also supports growth, with the nitrophenyl moiety serving as a versatile pharmacophore.

MARKET CHALLENGES

Regulatory and handling constraints associated with nitroaromatic compounds, limited scale of commercial demand, and stringent quality and enantiomeric purity standards pose significant challenges for suppliers and end users.

MARKET RESTRAINTS

Competition from alternative chiral building blocks and synthetic routes, as well as supply chain fragmentation and dependency on specialty manufacturers, can constrain market expansion.

MARKET OPPORTUNITIES

Growth in contract research and custom synthesis services, along with expanding applications in asymmetric organocatalysis research, provide notable opportunities for market players.

Segment Analysis

Segment Category	Sub‑Segments	Key Insights
By Type	Pharmaceutical Grade Technical Grade Research Grade	Pharmaceutical Grade leads the segment due to its exceptional enantiomeric purity and stringent quality controls, making it the preferred choice for advanced drug synthesis where precision and regulatory compliance are paramount.
By Application	Pharmaceutical Intermediates Research Chemicals Agrochemical Synthesis Others	Pharmaceutical Intermediates dominates as the core application, serving as a versatile chiral building block in the synthesis of bioactive compounds.
By End User	Pharmaceutical Companies Contract Research Organizations Academic Institutions Chemical Manufacturers	Pharmaceutical Companies are the primary end users, leveraging the compound’s unique stereochemistry for scalable production of high‑value APIs.
By Synthesis Method	Asymmetric Hydrogenation Chemical Resolution Enzymatic Resolution	Asymmetric Hydrogenation emerges as the leading method, prized for its scalability, high yield, and stereoselectivity.
By Distribution Channel	Direct Sales Distributors Online Platforms	Direct Sales prevails in this niche market, providing end users with customized specifications and rapid delivery.

Competitive Landscape

Leading players are predominantly based in China, with companies such as Hairui Chemical and Capot Chemical capturing over 60% of global supply. Emerging players from Ukraine and Switzerland, including Enamine and Biosynth, are expanding through green chemistry and scalable enantioselective processes.

Top 10 Companies in the (S)-(4-Nitrophenyl) ethylamine (CAS 4187-53-5) Market

1️⃣ TCI Chemicals

Headquarters: Tokyo, Japan
Key Offering: High‑purity chiral amines, API intermediates, custom synthesis services

TCI Chemicals is a global leader in specialty chemicals, offering a broad portfolio of enantiopure intermediates. Their robust quality assurance and GMP‑compliant manufacturing support pharmaceutical and fine‑chemical applications worldwide.

Sustainability & Growth Initiatives:

• Investment in continuous‑flow asymmetric hydrogenation technologies
• Partnerships with academic institutions for green chemistry research
• Expansion of digital chemical marketplace platform for broader market reach

2️⃣ Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany
Key Offering: Premium chiral reagents, API intermediates, analytical services

Sigma‑Aldrich, part of Merck KGaA, provides high‑quality chiral building blocks with extensive analytical support, facilitating research and development across pharmaceuticals and agrochemicals.

Sustainability & Growth Initiatives:

• Development of biodegradable chiral auxiliaries
• Implementation of ISO 9001 and ISO 14001 certifications
• Digital lab notebooks for real‑time data sharing with customers

3️⃣ Alfa Aesar

Headquarters: Haverhill, USA
Key Offering: Research‑grade chiral amines, custom synthesis, technical support

Alfa Aesar delivers high‑purity chiral intermediates with flexible packaging options, catering to academic labs and early‑stage pharmaceutical projects.

Sustainability & Growth Initiatives:

• Adoption of green solvent systems in synthesis processes
• Collaboration with universities for chiral catalyst development
• Enhanced traceability through blockchain‑based batch records

4️⃣ Hairui Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Large‑scale production of (S)-(4‑Nitrophenyl) ethylamine, GMP‑qualified intermediates

Hairui Chemical has established extensive manufacturing facilities, delivering high‑purity chiral intermediates to global pharmaceutical clients with competitive pricing.

Sustainability & Growth Initiatives:

• Implementation of water‑recycling systems in production lines
• ISO 9001 and ISO 14001 certifications for quality and environmental management
• R&D partnership with Chinese universities for novel chiral resolutions

5️⃣ Capot Chemical Co., Ltd.

Headquarters: Guangzhou, China
Key Offering: Custom chiral synthesis, API intermediates, analytical support

Capot Chemical specializes in tailored synthesis of chiral amines, offering rapid turnaround for research and development projects.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources for manufacturing
• Development of scalable asymmetric hydrogenation protocols
• Digital platform for real‑time inventory and order tracking

6️⃣ Chemenu Inc.

Headquarters: Shenzhen, China
Key Offering: High‑purity chiral intermediates, custom synthesis, analytical services

Chemenu provides a wide range of chiral building blocks with a focus on pharmaceutical and fine‑chemical applications, backed by robust quality control.

Sustainability & Growth Initiatives:

• Investment in solvent‑free synthesis routes
• Partnerships with biotech firms for chiral catalyst development
• Implementation of AI‑driven process optimization tools

7️⃣ Biosynth AG

Headquarters: Zürich, Switzerland
Key Offering: Enzymatic resolution, chiral auxiliaries, green chemistry solutions

Biosynth leverages biocatalysis to produce enantiopure intermediates with minimal environmental impact, targeting both pharmaceutical and agrochemical sectors.

Sustainability & Growth Initiatives:

• Expansion of biocatalytic platforms for large‑scale production
• Collaboration with European research institutes on green synthesis
• ISO 9001 and REACH compliance for all products

8️⃣ Enamine LLC

Headquarters: Kyiv, Ukraine
Key Offering: Chiral building blocks, library synthesis, custom services

Enamine offers a comprehensive library of chiral amines, supporting medicinal chemistry and academic research with fast delivery and high purity.

Sustainability & Growth Initiatives:

• Development of low‑energy synthesis protocols
• Digital chemical marketplace integration for global reach
• Partnerships with CROs for early‑stage synthesis

9️⃣ Bide Pharma Tech Ltd.

Headquarters: Nanjing, China
Key Offering: GMP‑qualified intermediates, custom synthesis, analytical support

Bide Pharma Tech focuses on high‑purity chiral intermediates for pharmaceutical manufacturing, ensuring compliance with global regulatory standards.

Sustainability & Growth Initiatives:

• Implementation of waste‑minimization protocols
• Collaboration with Chinese regulatory bodies for streamlined approvals
• Digital supply‑chain transparency platform

🔟 SynQuest Labs, Inc.

Headquarters: San Diego, USA
Key Offering: Custom chiral synthesis, API intermediates, analytical services

SynQuest Labs provides bespoke chiral building blocks with a focus on innovative drug discovery and fine‑chemical applications.

Sustainability & Growth Initiatives:

• Investment in continuous‑flow synthesis
• Partnerships with biotech startups for chiral catalyst development
• Implementation of green chemistry training programs for chemists

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/307707/ethylamine-market

Get Full Report Here: https://www.24chemicalresearch.com/reports/307707/ethylamine-market

Outlook

Over the forecast period, the (S)-(4‑Nitrophenyl) ethylamine market is expected to expand steadily, driven by increased demand for enantiopure intermediates in pharmaceutical development and the growing adoption of asymmetric synthesis technologies. The Asia‑Pacific region will continue to dominate production due to cost‑effective manufacturing capabilities and strong domestic pharmaceutical demand, while Europe will maintain a robust market share driven by stringent regulatory compliance and a focus on sustainable chemical processes.

Future Trends

• Accelerated development of biocatalytic and enzymatic resolution methods to reduce production costs and environmental impact.
• Integration of digital chemical marketplaces and blockchain for enhanced traceability and rapid procurement.
• Growing emphasis on green chemistry initiatives, including solvent‑free synthesis and renewable energy utilization in manufacturing.
• Expansion of contract research and manufacturing services (CRAMS) to support early‑stage drug discovery and custom synthesis needs.
• Increased collaboration between academia and industry to develop novel chiral catalysts and organocatalysts.